What are the main recommendations for clinical trial
design during the COVID-19 pandemic?
Hundreds of registered clinical trials regarding potential therapies for
COVID-19 are currently open in international registries. The study
designs and outcomes are often divergent and based on a single center’s
experience or compassionate use of the candidate treatments. To improve
the quality of the evidence and secondary analysis, the scientific
community should lead multi-center, multi-arm and highly powered
clinical trials and foster the global sharing of knowledge on the
COVID-19. This approach would empower the generation of high-quality
data on efficacy and safety of potential therapies for
COVID-19.180